Lilly sues two medical spas over copycat weight-loss drugs
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...
CNBC on MSN22d
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions – NBC Los Angeles
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
Business Insider22d
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
Earlier in December, telehealth company Ro announced a partnership with Eli Lilly to offer a half-price version of Zepbound, Lilly's brand-name tirzepatide product. The cheaper option is sold in ...